Alshaikh, A. A., Al-Qahtani, F. S., Taresh, H. M. N., Hayaza, R. A. A., Alqhtani, S. S. M., Summan, S. I., Al Mansour, S. A., Alsultan, O. H. A., Asiri, H. Y. M., Alqahtani, Y. M. S., Alzailaie, W. K. A., Alamoud, A. A. A., & Ghazy, R. M. (2024). Prediction of diabetes and prediabetes among the Saudi population using a non-invasive tool (AUSDRISK). Medicina, 60(5), 775.

Araujo-Castro, M., Pascual-Corrales, E., & Lamas, C. (2023). Possible, probable, and certain hypercortisolism: A continuum in the risk of comorbidity. Annales d’Endocrinologie, 84(2), 272–284.

Bakr, O. (2021). The evaluation of Hba1c test as a diagnostic test for diabetes mellitus type 2. Journal of Education and Science, 30(3), 95–103.

Belkacem, S. (2021). The optimal HbA1c threshold for predicting diabetes mellitus defined by OGTT in a high-risk population in Algiers about 500 cases. Endocrine Abstracts, 73, AEP257.

Bhasin, S., Lincoff, A. M., Nissen, S. E., Wannemuehler, K., McDonnell, M. E., Peters, A. L., Khan, N., Snabes, M. C., Li, X., Li, G., Buhr, K., Pencina, K. M., & Travison, T. G. (2024). Effect of testosterone on progression from prediabetes to diabetes in men with hypogonadism. JAMA Internal Medicine, 184(4), 353–362.

Boswell, L., Amor, A. J., Montagud-Marrahi, E., Casals, G., Díaz-Catalan, D., Banon-Maneus, E., Ramírez-Bajo, M. J., Hierro, N., Diekmann, F., Musquera, M., Serés-Noriega, T., Esmatjes, E., Ferrer-Fàbrega, J., Ventura-Aguiar, P., & Hanzu, F. A. (2023). Midnight cortisol is associated with changes in systolic blood pressure and diabetic neuropathy in subjects with type 1 diabetes undergoing simultaneous kidney-pancreas transplantation. Diabetes Therapy, 15(1), 165–181.

Boye, K. S., Lage, M. J., Shinde, S., Thieu, V., & Bae, J. P. (2021). Trends in HbA1c and body mass index among individuals with type 2 diabetes: Evidence from a US database 2012–2019. Diabetes Therapy, 12(7), 2077–2087.

Caliber, M., & Saad, F. (2021). Testosterone therapy for prevention and reversal of type 2 diabetes in men with low testosterone. Current Opinion in Pharmacology, 58, 83–89.

Cao, C., Hu, H., Zheng, X., Zhang, X., Wang, Y., & He, Y. (2022). Association between central obesity and incident diabetes mellitus among Japanese: A retrospective cohort study using propensity score matching. Scientific Reports, 12(1), 13445.

Chandrasekaran, P., & Weiskirchen, R. (2024). The role of obesity in type 2 diabetes mellitus – an overview. International Journal of Molecular Sciences, 25(3), 1882.

Corona, G., Vena, W., Pizzocaro, A., Vignozzi, L., Sforza, A., & Maggi, M. (2022). Testosterone therapy in diabetes and pre-diabetes. Andrology, 11(2), 204–214.

Dehghan, S., Mohammadianamiri, F., Yazdani, S., Musavi, H., Bouzari, S. Z., Mesbah, S., Bayani, M. A., Abedi Samakoush, M., Bouzari, Z., & Ebrahim, E. (2023). Can glycosylated hemoglobin and fasting blood sugar replace glucose challenge test in screening for gestational diabetes? International Journal of Women’s Health and Reproduction Sciences, 11(3), 132–137.

Deveci, O., Karaca, Z., Tanriverdi, F., Deveci, K., Hacioglu, A., Unluhizarci, K., & Kelestimur, F. (2023). Prediabetes and mild hepatosteatosis are associated with blunted cortisol response to glucagon but not to growth hormone. Annales d’Endocrinologie, 84(2), 254–259.

Echouffo-Tcheugui, J. B., Perreault, L., Ji, L., & Dagogo-Jack, S. (2023). Diagnosis and management of prediabetes. Journal of the American Medical Association, 329(14), 1206–1216.

Felix, K., Medina, R., Weigensberg, M., & Toledo-Corral, C. (2024). The association between morning serum cortisol and prediabetes status is modified by socioeconomic status among youth from minoritized communities. Psychoneuroendocrinology, 160, 106813.

Hami, M. A., Mosa, A. A., Hami, I. A., Saeed, A. Y., Mohammed, Q. O., Mousa, M. A., & Salih, M. A. (2023). Diagnostic values and trace element status in prediabetes and diabetes mellitus. Clinical Nutrition Open Science, 52, 193–201.

Han, Y., Hu, H., Li, Q., Deng, Z., & Liu, D. (2023). Triglyceride glucose-body mass index and the risk of progression to diabetes from prediabetes: A 5-year cohort study in Chinese adults. Frontiers in Public Health, 11, 1028461.

Hara, K., Hirase, T., Pathadka, S., Cai, Z., Sato, M., Ishida, N., & Takemura, R. (2024). Trends of HbA1c and BMI in people with type 2 diabetes: A Japanese claims-based study. Diabetes Therapy, 15(4), 801–817.

Ho, C.-H., Yu, H.-J., Wang, C.-Y., Jaw, F.-S., Hsieh, J.-T., Liao, W.-C., Pu, Y.-S., & Liu, S.-P. (2013). Prediabetes is associated with an increased risk of testosterone deficiency, independent of obesity and metabolic syndrome. PLoS One, 8(9), e74173.

Hu, Y., Yuan, L., Bao, Y., Wang, Y., Cai, T., Ma, J., & Ding, B. (2023). Low total testosterone levels in men with newly diagnosed early-onset type 2 diabetes: A cross-sectional study in China. Journal of Diabetes Research, 2023, 2082940.

Jabbar, A. A., & Majeed, M. J. (2020). The effect of serum cortisol on the prediabetes stage under normal and stress state. IOP Conference Series: Materials Science and Engineering, 928(5), 052019.

Khan, S. U., Akram, M., Iqbal, Z., Javid, M., Unab, S., Jannat, S., Ali, A., Khan, M. F., Ali, W., Rafi, M., Qayyum, M., & Rizvi, S. R. (2022). Relationship between testosterone and cortisol levels and body mass index in men with type 2 diabetes mellitus. Romanian Journal of Diabetes Nutrition and Metabolic Diseases, 29(3), 341–348.

Kumari, K., Kumar, R., Memon, A., Kumari, B., Tehrim, M., Kumari, P., Shehryar, M., Islam, H., Islam, R., Khatri, M., Kumar, S., & Kumar, A. (2023). Treatment with testosterone therapy in type 2 diabetic hypogonadal adult males: A systematic review and meta-analysis. Clinics and Practice, 13(2), 454–469.

Kunin-Batson, A. S., Crain, A. L., Gunnar, M. R., Kelly, A. S., Kharbanda, E. O., Haapala, J., Seburg, E. M., Sherwood, N. E., & French, S. A. (2023). Household income, cortisol, and obesity during early childhood: A prospective longitudinal study. The Journal of Pediatrics, 252, 76–82.

Kwok, M. K., Kawachi, I., Rehkopf, D., & Schooling, C. M. (2020). The role of cortisol in ischemic heart disease, ischemic stroke, type 2 diabetes, and cardiovascular disease risk factors: A bi-directional Mendelian randomization study. BMC Medicine, 18(1), 363.

Leutner, M., Matzhold, C., Bellach, L., Wohlschläger-Krenn, E., Winker, R., Nistler, S., Endler, G., Thurner, S., Klimek, P., & Kautzky-Willer, A. (2021). Increase in testosterone levels is related to a lower risk of conversion of prediabetes to manifest diabetes in prediabetic males. Wiener Klinische Wochenschrift, 134(1–2), 1–6.

Lundqvist, M. H., Pereira, M. J., Almby, K., Hetty, S., & Eriksson, J. W. (2023). Regulation of the cortisol axis, glucagon, and growth hormone by glucose is altered in prediabetes and type 2 diabetes. The Journal of Clinical Endocrinology and Metabolism, 109(2), e675–e688.

Malik, A. W., Abood, A. A., & Mohammad, S. Q. (2023). Association between the proinflammatory cytokine IL-17F and Helicobacter pylori infection in a sample of Iraqi patients. International Journal of Biomedicine, 13(2), 338–341.

Maliszewska, K., Adamska-Patruno, E., & Kretowski, A. (2019). The interplay between muscle mass decline, obesity, and type 2 diabetes. Polish Archives of Internal Medicine, 129(11), 809–816.

Mei, Y., Lyu, Y., Zhao, Z., & Li, Y. (2022). Circulating fibroblast growth factor 21 and total testosterone in type 2 diabetes mellitus men with coronary heart disease. Frontiers in Endocrinology, 13, 912243.

Mody, L., & Covinsky, K. E. (2024). Testosterone replacement therapy and diabetes in men with hypogonadism. JAMA Internal Medicine, 184(4), 362.

Patel, H., & Anuradha, N. (2023). Comparative analysis of fructosamine and HbA1c as a glycemic control marker in type 2 diabetes patients in a tertiary care hospital study. Asian Journal of Medical Sciences, 14(10), 73–78.

Pourat, N., Chen, X., Lu, C., Zhou, W., Hair, B., Bolton, J., & Sripipatana, A. (2022). Ensuring equitable care in diabetes management among patients of Health Resources and Services Administration – Funded Health Centers in the United States. Diabetes Spectrum, 36(1), 69–77.

Rooney, M. R., Fang, M., Ogurtsova, K., Ozkan, B., Echouffo-Tcheugui, J. B., Boyko, E. J., Magliano, D. J., & Selvin, E. (2023). Global prevalence of prediabetes. Diabetes Care, 46(7), 1388–1394.

Shi, Y., & Wen, M. (2023). Sex-specific differences in the effect of the atherogenic index of plasma on prediabetes and diabetes in the NHANES 2011–2018 population. Cardiovascular Diabetology, 22(1), 19.

Steffensen, C., Thomsen, H. H., Dekkers, O. M., Christiansen, J. S., Rungby, J., & Jørgensen, J. O. L. (2016). Low positive predictive value of midnight salivary cortisol measurement to detect hypercortisolism in type 2 diabetes. Clinical Endocrinology, 85(2), 202–206.

Sun, S., & Wang, Y. (2023). Relationship between cortisol and diabetic microvascular complications: A retrospective study. European Journal of Medical Research, 28(1), 391.

Swamy, N. A., Mulimani, M. S., & Ambali, A. P. (2021). Combined detection of prediabetes using HBA1C and fasting blood sugar levels. International Journal of Health and Clinical Research, 4(19), 248–251.

Wang, L., Peng, W., Zhao, Z., Zhang, M., Shi, Z., Song, Z., Zhang, X., Li, C., Huang, Z., Sun, X., Wang, L., Zhou, M., Wu, J., & Wang, Y. (2021). Prevalence and treatment of diabetes in China, 2013–2018. Journal of the American Medical Association, 326(24), 2498–2506.

Wu, V.-C., Chan, C.-K., Wu, W.-C., Peng, K.-Y., Chang, Y.-S., Yeh, F.-Y., Chiang, J.-Y., Lee, Y.-J., Liu, K.-L., Wang, S.-M., Lin, Y.-H., Chueh, J. S., Lai, T.-S., Chueh, S.-C. J., Yang, S.-Y., Liu, K.-L., Chang, C.-C., Lee, B.-C., … Wu, V.-C. (2022). New-onset diabetes mellitus risk associated with concurrent autonomous cortisol secretion in patients with primary aldosteronism. Hypertension Research, 46(2), 445–455.

Yan, Z., Cai, M., Han, X., Chen, Q., & Lu, H. (2023). The interaction between age and risk factors for diabetes and prediabetes: A community-based cross-sectional study. Diabetes, Metabolic Syndrome and Obesity, 16, 85–93.

Yao, Q., Wang, B., An, X., Zhang, J., & Ding, L. (2018). Testosterone level and risk of type 2 diabetes in men: A systematic review and meta-analysis. Endocrine Connections, 7(1), 220–231.

Yassin, A., Haider, A., Haider, K. S., Caliber, M., Doros, G., Saad, F., & Garvey, W. T. (2019). Testosterone therapy in men with hypogonadism prevents progression from prediabetes to type 2 diabetes: Eight-year data from a registry study. Diabetes Care, 42(6), 1104–1111.

Yazdanpanah, Z., Kazemipour, N., Kalantar, S. M., & Vahidi Mehrjardi, M. Y. (2022). Plasma miR-21 as a potential predictor in prediabetic individuals with a positive family history of type 2 diabetes mellitus. Physiological Reports, 10(2), e15163.

Yokota, K., & Sone, M. (2023). Autonomous cortisol secretion in patients with primary aldosteronism: A possible risk factor for new-onset diabetes mellitus. Hypertension Research, 46(3), 803–805.

Zhang, X., Deng, X., Zhou, J., Qiu, K., Deng, M., Lin, Z., Mosha, S. S., & Li, W. (2020). The association of serum cortisol level with microalbuminuria in patients with type 2 diabetes and prediabetes. International Journal of Medical Sciences, 17(18), 2998–3004.